

CURRICULUM VITAE

Dr Anke. E Hensiek, Dr Med, PhD, FRCP

Affiliated Assistant Professor University of Cambridge

E-Mail: ahensiek@nhs.net

PA (Ms Kayleigh Shough) : kayleigh.shough@nhs.net

Profile/Summary:

- Consultant Neurologist Addenbrookes Hospital, Cambridge and Queen Elizabeth Hospital, Kings Lynn
- Excellent broad clinical experience in general neurology
- Strong academic background and continuing interest in clinical research
- Subspecialty interest in clinical neurogenetics, including regional/national specialist clinics for neurofibromatosis type 2, tuberous sclerosis and ataxia
- Medicolegal experience since 2009 including personal injury, negligence reports and work for NHS resolution and GMC

Content :

• Personal details and qualifications:	2
• Membership of professional organizations	2
• Scholarships and Awards	3
• Education	3
• Previous posts	3
• Management and leadership	5
• Teaching and education	5
• Research and grants	5
• Clinical experience	6
• Medicolegal experience	6
• Terms and conditions	7
• Publications	8

Personal details:

Date of Birth: April 15th, 1966

Nationality: British and German

Medical qualifications:

- German Staatsexamen (1994), University of Duesseldorf, Germany. Passed with “excellent”
- German “Doctor Medicinae” (1997), University of Duesseldorf, “Magna Cum Laude”
- FMGEMS (Foreign Medical Graduate Exam) part 1 (1992), USMLE (United States Medical Licensing Exam) part 2 (1994)
- MRCP part 1 (June 1996); MRCP part 2 (June 1998)
- Doctor of Philosophy (May 2004), University of Cambridge

GMC registration: Full registration, No 4342962

Date of CCT completion: March 18, 2008

Membership of professional organizations:

- Fellow of Royal College of Physicians London
- Association of British Neurologists
- European Academy of Neurology
- British Medical Association

Current post:

Consultant Neurologist

Addenbrookes Hospital
Hills Road
Cambridge CB2 2QQ

Queen Elizabeth Hospital
Gayton Road
Kings Lynn PE30 4ET

SCHOLARSHIPS AND AWARDS

Beverly and Sackler Scholarship	2000, 2001, 2002
Wellcome Research Training Fellowship	1999
Clinical Excellence Award level 3	2018
CUH Students Teaching Award (ClinSoc)	2020

EDUCATION

General Education:

1973 - 1985	Primary and secondary school in Buende, Germany
-------------	--

Medical Education:

1986 - 1994	Medical School of the University of Duesseldorf, Germany
-------------	---

Undergraduate Research

1990 – 1993	<i>“Event related potentials (P 300) in asymptomatic HIV-patients”</i> Department of Neurology, University of Duesseldorf, Germany
-------------	--

PREVIOUS APPOINTMENTS

Internship:

<u>House Physician</u> Monklands Hospital Airdrie ML6 OJS	2/1995 – 8/1995
---	-----------------

<u>House Physician/Surgeon</u> North Middlesex Hospital London, N18 1QX	8/1995 – 8/1996
---	-----------------

Senior House Officer:

<u>SHO Neurology /Neurosurgery</u>	8/1996 – 2/1997
<u>SHO Rotation General Medicine/Neurology</u>	2/1997 – 2/1999

Oldchurch Hospital
Romford, Essex RM7 OBE

Senior House Officer Neurology

5/1999 – 11/1999

The National Hospital for Neurology and Neurosurgery
Queen Square, London WC1N 3BG

Research:

Wellcome Research Training Fellow

“Searching for susceptibility genes in Multiple Sclerosis”

Cambridge University Dep. for Clinical Neuroscience

12/1999 – 10/2003

Specialist Registrar

Specialist Registrar Neurology

Norfolk and Norwich University Hospital
Colney Lane, Norwich

11/2003 – 6/2004

02/2006 – 9/2006; 2/2008

Specialist Registrar Neurology

The National Hospital for Neurology and Neurosurgery
Queen Square, London WC1N 3BG

7/2004 – 5/2005

10/2007 – 1/2008

Specialist Registrar Neurology

Addenbrooke's Hospital
Hills Road, Cambridge CB2 2QQ

5/2005 – 1/2006

10/2006 – 11/2006; 6/2007 – 9/2007

Consultant

Consultant Neurologist

Since 3/2008

Addenbrookes Hospital
Hills Road
Cambridge

Queen Elizabeth Hospital
Colney Lane
Kings Lynn

Consulting Rooms

The Cambridge Spire Lea Hospital, Cambridge

The Nuffield Hospital, Cambridge

COMITTEES AND MANAGEMENT ROLES

- East of England RDN specialist lead for neurological disorders (since 2023)
- Co-Chair ataxia telangiectasia committee for clinical trials (since 2022)
- Member of ataxia telangiectasia subcommittee 1M1M network (since 2021)
- Member scientific advisory board ataxia telangiectasia society (since 2018)

TEACHING AND EDUCATION

- Educational supervisor neurology Addenbrookes Hospital (since 2012)
- Coordinator SSPE neurogenetics at CUH (since 2020)
- CPD assessor neurology, Royal College of Physicians (since 2022)

RESEARCH and GRANTS:

NIHR portfolio studies:

- Principal investigator: International Neuroimaging Collaboration for Ataxia-Telangiectasia (INCAT)
- Principal investigator: Ataxia Telangiectasia: Clinical and Genetic Features
- Co-investigator - Genotype and Phenotype in Inherited Neurodegenerative Diseases -
- Co- Principal investigator: - Trial REadiness in Ataxia Telangiectasia (TREAT-AT)

Grants:

- Wellcome Research Training Fellowship (2000-2003)
- Co-PI Action for AT grant (Trial Readiness in Ataxia Telangiectasia) - £250,000 (2023 - 2025)

CLINICAL EXPERIENCE

I have excellent experience in general medicine as well as clinical and academic neurology. My current post as a consultant neurologist since 2008 involves assessing patient on an outpatient and inpatient basis, as well as on the intensive care unit. In my clinical practise I manage patients with all common and rare neurological disorders, including epilepsy, headinjury, headache, pain, dizziness, Parkinson's Disease, neuropathies, memory problems, muscle diseases, movement disorders and Multiple Sclerosis. Whilst the majority of my work involves general neurology, I have a subspecialty interest in neurogenetics and I conduct specialised neurogenetics clinics in Cambridge, including leading regional. clinics on ataxia and tuberous sclerosis. Furthermore, I am the neurology lead for national clinics for Neurofibromatosis type 2 and contribute to the development for assessment protocols and clinical studies into these disorders.

MEDICOLEGAL EXPERIENCE

I have personal injury and medical negligence experience since 2009 and currently receive an average of 90 instructions per year, which comprise of roughly 90% claimant and 10% defendant reports. I also prepare reports for NHS resolution and the General Medical Council. Attendance at court as required.

MEDICLEGAL COURSES ATTENDED

Standard medico-legal course, London, 2010

Medico-legal court room skills course, London, 2015

Cambridge Annual Medico-Legal Conference, 2022, 2023

TERMS AND CONDITIONS

My current hourly rate is £350 plus VAT for all time spent on the case. Itemised billing and copies of receipts will be provided if requested.

Draft report produced within two to six weeks (depending on complexity).

Report for court completed two weeks following return of draft.

Attendance at court will be charged at a daily rate of £2000 plus VAT. I will require at least eight weeks notice for attendance at court hearing and any cancellations of less than 4 weeks notice will be charged at the full rate. Travel time will be charged at £200 plus VAT per hour in addition to reimbursement of travel expenses, overnight stays will be charged at £500 plus VAT per night in addition to reimbursement of hotel expenses.

I reserve the right to charge a fee of £500 plus VAT for nonattendance or cancellation within 48 hours providing the case is rescheduled. For a cancellation of instruction when I have already worked on the case, I would charge the hourly fee of £350 plus VAT for the time I have already spent, in addition to DNA fee of £500 plus VAT.

My report will only include review of medical records that have been received by the time of the scheduled outpatient appointment. Any medical records that are received after assessment of client and completion of my report will be assessed as part of an addendum report which would incur an additional fee.

Should accounts not be settled within four months of invoice, at my discretion, I have the right to charge interest on unpaid accounts at the rate of 5% a month, or part of a month, until full settlement is received.

Invoices are payable in full within six months of invoice date, regardless of the Instructor being in funds or not and are not subject to reduction or clawback in the event of Court Assessment and or settlement terms with other parties.

In the event that the case file is transferred from the Instructor to another solicitor or medico legal company; liability for any invoice remains with the Instructor.

PUBLICATIONS:

A. Articles

1. Tiet MY, ... **Hensiek AE**, Horvath R: Biomarkers in Ataxia Telangiectasia – a systematic Review. J Neurol 2025;272(2):110. doi: 10.1007/s00415-024-12766-7.
2. Tiet MY,...**Hensiek AE**: A novel biomarker for Ataxia Telangiectasia: Evaluating the lack of hypointensity of the dentate nuclei. JNNP 2025, 96(2):202-204
3. Major T, ..**Hensiek AE**: Validation of the ataxia telangiectasia neurological examination scale toolkit (AT-NEST) for use in adults with ataxia telangiectasia. Cerebellum 2024, 23 (2); 455-458
4. Lam T, ..., **Hensiek A**, ..Tucci A: Repeat expansions in NOP56 are a cause of spinocerebellar ataxia type 36 in the British population, Brain Commun. 2023 ;5(5):fcad244
5. Wilson A, **Hensiek AE**, Jones, M, Scoffings D. Labrune syndrome and pregnancy : case report. Obstetric medicine 2023, in press
6. Tiet M, ... **Hensiek AE**: White matter hyperintensities and cerebral microbleeds in Ataxia Telangiectasia. Neurology Genetics 2021;7(6): e640
7. Nakornchai T, Conci E, **Hensiek, AE**, Brown JWK. Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic. Postgrad Med J 2021;141234-41
8. Tiet M, Horvath R, **Hensiek AE**: Ataxia Telangiectasia – what the neurologist needs to know. Pract Neurol 2020, 20(5):404-414
9. Schon K, ..., **Hensiek AE**. : Genotype, extrapyramidal features and severity of variant Ataxia-Telangiectasia. Ann Neurol. 2019, 85(2):170-180
10. Van Os NJH, **Hensiek A**, et al: Trajectories of motor abnormalities in milder phenotypes of ataxia telangiectasia. Neurology. 2019 Jan 1;92:e19-e29
11. Morris, KA ... , **Hensiek A** ,Parry A: The response of spinal cord Ependymomas to Bevacizumab in patients with Neurofibromatosis type 2. J Neurosurg Spine. 2016 Dec 16:1-9
12. **Hensiek AE**, Taylor AMR: The clinical variability of Ataxia Telangiectasia – an update. ACNR 2015; 15(2): 8- 12
13. **Hensiek A**, Kirker S, Evan E: Diagnosis, investigation and management of hereditary spastic paraplegia in the era of next generation sequencing. J Neurol 2015; 262 (7): 1601 – 12
14. Tysome JR,..., **Hensiek A**,..., Axon PR. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol. 2012 Apr;33(3):466-72
15. **Hensiek AE**,et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007, 30;68(5):376-83
16. **Hensiek AE**, Absalom T: Status epilepticus. Anaesthesia and Intensive Care medicine 2006.7 (4); 127 – 128
17. Vera J, **Hensiek A** et al: Ophthalmoplegia and slurred speech in an intravenous drug user, PLoS Medicine 2006, 3(12):e453
18. The Games Collaborative Group,... **Hensiek AE** ... et al : Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, J Neuroimmunol. 2006 Oct;179(1-2):108-16.
19. Roxburgh RH, Sawcer S, Maranian M, Seaman S, **Hensiek A**, Yeo T, Geans J, Compston A: No evidence for a significant role of CTLA-4 in multiple sclerosis. J Neuroimmunol 2006, 171 (1-2); 193 – 197
20. Roxburgh RH, Seaman SR, Mastermann T, **Hensiek AE** et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate severity. Neurology 2005; 64 (7): 1144 - 1151
21. **Hensiek AE**,et al. Updated results of the United Kingdom linkage based genome screen in multiple sclerosis. J Neuroimmunol 2003, 143 (1-2): 25 - 30
22. Åkesson E, Coraddu F, Marrosu M, Massacesi L, **Hensiek A**,et al.: Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. J Neuroimmunol 2003; 143 (1-2): 31- 38
23. Yeo TW,. **Hensiek A**, ..Sawcer S. Refining the analysis of whole genome linkage disequilibrium association map: the United Kingdom. J Neuroimmunol 2003; 143 (1-1): 53 – 59
24. Weber A, Infante-Duarte C, Sawcer S, Setakis E, Bellmann-Strobl J, **Hensiek A** et al:A genome-wide German screen for linkage disequilibrium in multiple sclerosis. J Neuroimmunol 2003, 143 (1-2):79 - 83
25. Eraksoy M*, **Hensiek A***, et al: A genome screen for linkage disequilibrium in Turkish multiple sclerosis. J Neuroimmunol 2003, 143 (1-2): 129 - 132
26. **Hensiek AE**, et al : Osteopontin gene and clinical severity of multiple sclerosis. J Neurol 2003, 250(8):943-7
27. **Hensiek AE**, Compston DA, Sawcer SJ : Searching for needles in haystacks-the genetics of multiple sclerosis and other common neurological diseases. Brain Res Bull. 2003; 15;61(3):229-34.
28. Sawcer S, Maranian M, **Hensiek A**, et al.: Crohn's associated NOD2 gene variants are not involved in determining susceptibility to multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74 (8): 1157
29. **Hensiek AE**, et al.: HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.. J Neurol Neurosurg Psychiatry. 2002;72 (2):184-7
30. Sawcer S, I Maranian M, Setakis E, Val Curwen V, Åkesson E, **Hensiek A** et al.: A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002, 125: 1337 – 1347
31. **Hensiek AE**, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J Neurol Neurosurg Psychiatry. 2002 ;72(3):281-5.
32. Coraddu F, Sawcer S, D'Alfonso S, Lai M, **Hensiek A**, Solla E, Broadley S, Mancosu C, Pugliatti M, Marrosu MG, Compston A.: A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet. 2001 ;9 (8):621-6

- 33 Broadley S, **Hensiek A**, .. Compston A. A genome screen for multiple sclerosis in Italian families. *Genes Immun.* 2001 Jun;2(4):205-10
- 34. **Hensiek AE**, Kellerman AJ, Hill JT.: Spontaneous regression of a solitary cerebral metastases in renal carcinoma and meningioma development under Medroxyprogesterone Acetate therapy . *Br J Neurosurg* 2000; 14 (4): 354 – 356

B. Book chapters

Trimble MR, **Hensiek AE**: On the use of psychotropic drugs in patients with seizure disorders. In: *The Neuropsychiatry of Epilepsy*. EDS Trimble M, Schmitz BE, Cambridge University Press, 2003,

Hensiek AE, Roxburgh R, Compston DAS: Genetic epidemiology of multiple sclerosis. In: *Neurology Blue Book series 2*, EDS McDonald WI, Noseworthy J, Butterworth 2003